Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.80
Bid: 66.80
Ask: 68.40
Change: 0.60 (0.91%)
Spread: 1.60 (2.395%)
Open: 67.00
High: 67.00
Low: 66.80
Prev. Close: 66.20
CCEP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Announces new company name and investor event

21 Apr 2021 07:00

RNS Number : 0932W
Coca-Cola European Partners plc
21 April 2021
 

 

21 April 2021

 

Coca-Cola European Partners plc (CCEP) today provides an update

on the acquisition of Coca-Cola Amatil Limited (CCL), announces new company name & combined Q1 trading update with an investor event on 11 May 2021

 

 

Transaction update

 

· At the Scheme Meeting on 16 April 2021, CCL's independent shareholders voted in favour of the proposed Scheme of Arrangement ("Scheme")

· On 20 April 2021 the Scheme received approval from the Supreme Court of New South Wales

· Consequently, on 21 April 2021, the Scheme became effective and will be implemented on 10 May 2021

 

New company name

Coca-Cola European Partners plc will be renamed Coca-Cola Europacific Partners plc following implementation of the Scheme on 10 May 2021.

 

 

The company will continue to be listed on Euronext Amsterdam, the New York Stock Exchange, London Stock Exchange and on the Spanish Stock Exchanges, and will continue to trade under the symbol "CCEP".

 

 

Q1 Trading update & investor event

CCEP will release its first-quarter 2021 trading update for the quarter ended 2 April 2021 at 07:00 BST, 08:00 CEST and 2:00 a.m. EDT on 11 May 2021.

On the same day, CCEP will also host a virtual event with investors and analysts, focused on providing more detail on the newly combined business. CCEP will webcast the main presentation through its website, www.cocacolaep.com beginning at 13:00 BST, 14:00 CEST and 7:00 a.m. EDT. A presentation will be followed by a panel Q&A session.

 

 

Further information

For more information on the transaction, please see our website www.cocacolaep.com 

 

Advisers

Rothschild & Co are acting as lead financial adviser. Credit Suisse are financial advisers to the Affiliated Transaction Committee (ATC) of the Board of Directors of CCEP. Macquarie Capital is also acting as a financial adviser to CCEP in connection with the transaction.

Slaughter and May and Corrs Chambers Westgarth are acting as legal counsel to CCEP.

 

Enquiries

Clare Wardle, General Counsel and Company Secretary: secretariat@ccep.com 

Investor Relations: Sarah Willett: sarah.willett@ccep.com +44 7970 145 218

Media:

Shanna Wendt: swendt@ccep.com +44 7976 595 168

Peter Brookes: pbrookes@citadelmagnus.com +61 407 911 389

Brett Clegg:  bclegg@citadelmagnus.com +61 487 436 985

 

About CCEP (LEI 549300LTH67W4GWMRF57)

Coca-Cola European Partners plc is a leading consumer goods company in Western Europe, making, selling & distributing an extensive range of non-alcoholic ready to drink beverages & is the world's largest Coke bottler based on revenue. CCEP serves a consumer population of over 300 million across Western Europe, including Andorra, Belgium, continental France, Germany, Great Britain, Iceland, Luxembourg, Monaco, the Netherlands, Norway, Portugal, Spain & Sweden. The Company is listed on Euronext Amsterdam, the New York Stock Exchange, London Stock Exchange & on the Spanish Stock Exchanges, trading under the symbol CCEP. For more information about CCEP, please visit www.cocacolaep.com & follow CCEP on Twitter at @CCEP.

 

 

 

About CCL

Coca-Cola Amatil Limited (including subsidiaries, group entities and related bodies corporate) is one of the largest bottlers and distributors of ready-to-drink non-alcohol and alcohol beverages and coffee in the Asia Pacific region. CCL is the authorised bottler and distributor of KO's beverage brands in Australia, New Zealand, Fiji, Indonesia, Papua New Guinea and Samoa. CCL directly employs around 12,000 people and indirectly creates thousands more jobs across the supply chain, partnering with key suppliers to bottle, package, sell and distribute its products. With access to around 270 million potential consumers through more than 630,000 active customers CCL is committed to leading through innovation, building a sustainable future and delivering long-term value, both to shareholders and to society.

 

For more information, visit www.ccamatil.com 

 

No incorporation of website information

The content of the websites referred to in this announcement is not incorporated into and does not form part of this announcement.

 

Forward-Looking Statements

This document contains statements, estimates or projections that constitute "forward-looking statements" concerning the financial condition, performance, results, strategy and objectives of Coca-Cola European Partners plc and its subsidiaries (together "CCEP"), CCEP's proposed acquisition (the "Acquisition") of Coca-Cola Amatil Limited and its subsidiaries (together "CCL") and the integration of CCL into CCEP. Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "plan," "seek," "may," "could," "would," "should," "might," "will," "forecast," "outlook," "guidance," "possible," "potential," "predict," "objective" and similar expressions identify forward-looking statements, which generally are not historical in nature.

Forward-looking statements are subject to certain risks that could cause actual results to differ materially from CCEP's and CCL's historical experience and present expectations or projections, including with respect to the Acquisition. As a result, undue reliance should not be placed on forward-looking statements, which speak only as of the date on which they are made. These risks include but are not limited to:

1. those set forth in the "Risk Factors" section of CCEP's 2020 Annual Report on Form 20-F, including the statements under the following headings: Business continuity and resilience (such as the adverse impact that the COVID-19 pandemic and related government restrictions and social distancing measures implemented in many of our markets, and any associated economic downturn, may have on our financial results, operations, workforce and demand for our products); Packaging (such as refillables and recycled plastics); Cyber and social engineering attacks and IT infrastructure; Economic and political conditions (such as the UK's exit from the EU, the EU-UK Trade and Cooperation Agreement, and uncertainty about the future relationship between the UK and EU); Market (such as disruption due to customer negotiations, customer consolidation and route to market); Legal, regulatory and tax (such as the development of regulations regarding packaging, taxes and deposit return schemes); Climate change and water (such as net zero emission legislation and regulation, and resource scarcity); Perceived health impact of our beverages and ingredients, and changing consumer buying trends (such as sugar alternatives and other ingredients); Competitiveness, business transformation and integration; People and wellbeing; Relationship with TCCC and other franchisors; Product quality; and Other risks; and

 

2. those set forth in the "Business and Sustainability Risks" section of CCL's 2020 Financial and Statutory Reports including the statements under the following headings: COVID-19 related risks; The Coca-Cola Company (TCCC) and other brand partners relationship risk; Economic and political risks; Cyber risk; Foreign exchange risk; Key personnel risk; Beverage industry risk; Regulatory risk; Corporate social responsibility risk; Climate change risk; Supply chain risk; Litigation and legal disputes risk; Malicious product tampering risk; Workplace Health & Safety (WHS) risk; Business interruption risk; Product quality risk; Fraud risk.

 

3. risks and uncertainties relating to the Acquisition, including the risk that the businesses will not be integrated successfully or such integration may be more difficult, time consuming or costly than expected, which could result in additional demands on CCEP's resources, systems, procedures and controls, disruption of its ongoing business and diversion of management's attention from other business concerns; the possibility that certain assumptions with respect to CCL or the Acquisition could prove to be inaccurate; the failure to receive, delays in the receipt of, or unacceptable or burdensome conditions imposed in connection with, all required regulatory approvals, shareholder approvals and the satisfaction of closing conditions to the Acquisition; ability to raise financing; the potential that the Acquisition may involve unexpected liabilities for which there is no indemnity; the potential failure to retain key employees of CCEP and CCL as a result of the proposed Acquisition or during integration of the businesses and disruptions resulting from the proposed Acquisition, making it more difficult to maintain business relationships; the potential if the Acquisition is not completed in a timely manner or at all for (i) negative reaction from financial markets, customers, regulators, employees and other stakeholders, (ii) loss of time spent on an unsuccessful Acquisition, and (iii) litigation related to the Acquisition.

 

The full extent to which the COVID-19 pandemic will negatively affect CCEP and/or CCL and the results of their operations, financial condition and cash flows will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the pandemic and actions taken by governmental authorities and other third parties in response to the pandemic.

 

Due to these risks, CCEP's and CCL's actual future results, dividend payments, and capital and leverage ratios may differ materially from the plans, goals, expectations and guidance set out in forward-looking statements (including those issued by CCL prior to the Acquisition). These risks may also adversely affect CCEP's share price. Additional risks that may impact CCEP's and CCL's future financial condition and performance are identified in filings with the United States Securities and Exchange Commission ("SEC") which are available on the SEC's website at www.sec.gov and at the Australian Stock Exchange which are available at www.asx.com.au. Neither CCEP nor CCL undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required under applicable rules, laws and regulations. Furthermore, neither CCEP nor CCL assumes any responsibility for the accuracy and completeness of any forward-looking statements. Any or all of the forward-looking statements contained in this filing and in any other of CCEP's or CCL's respective public statements (whether prior or subsequent to the Acquisition) may prove to be incorrect.

This document does not constitute or form part of any offer for sale or solicitation of any offer to buy any securities in the United States or elsewhere nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment to purchase securities. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended.

End

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CANVBLFLFZLBBBK
Date   Source Headline
23rd Mar 20204:25 pmRNSTransaction in Own Shares
23rd Mar 20207:00 amRNSFY20 GUIDANCE WITHDRAWAL, SHARE BUYBACK SUSPENSION
20th Mar 20205:00 pmRNSDirector/PDMR Shareholding
18th Mar 20205:30 pmRNSDirector/PDMR Shareholding
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn
18th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20202:30 pmRNSDirector/PDMR Shareholding
16th Mar 20206:00 pmRNSTransaction in Own Shares
16th Mar 20207:04 amRNSAnnual Financial Report
11th Mar 20203:30 pmRNSDirectorate Change
9th Mar 20203:15 pmRNSTransaction in Own Shares
6th Mar 202012:21 pmRNSRelease of the Guarantee
2nd Mar 20205:00 pmRNSTotal Voting Rights
2nd Mar 20204:00 pmRNSTransaction in Own Shares
24th Feb 20201:00 pmRNSTransaction in Own Shares
21st Feb 20204:00 pmRNSDirector/PDMR Shareholding
13th Feb 20207:00 amRNSPreliminary Unaudited Results FY 31 Dec 2019
3rd Feb 20202:00 pmRNSTotal Voting Rights
22nd Jan 20204:30 pmRNSDirector/PDMR Shareholding
2nd Jan 202011:30 amRNSTotal Voting Rights
23rd Dec 20193:30 pmRNSDirector/PDMR Shareholding
17th Dec 20193:00 pmRNSDirector/PDMR Shareholding
4th Dec 20194:00 pmRNSDirector/PDMR Shareholding
2nd Dec 20193:30 pmRNSTotal Voting Rights
20th Nov 20194:30 pmRNSDirector/PDMR Shareholding
15th Nov 201911:30 amRNSTransaction in Own Shares
8th Nov 201911:30 amRNSTransaction in Own Shares
1st Nov 20192:30 pmRNSTotal Voting Rights
1st Nov 20192:00 pmRNSTransaction in Own Shares
29th Oct 20194:30 pmRNSDirector/PDMR Shareholding
25th Oct 201912:30 pmRNSTransaction in Own Shares
24th Oct 20197:00 amRNSQ3 Trading Update & Interim Dividend Declaration
18th Oct 20192:00 pmRNSTransaction in Own Shares
11th Oct 20191:00 pmRNSTransaction in Own Shares
8th Oct 201910:30 amRNSDirector/PDMR Shareholding
4th Oct 201912:30 pmRNSTransaction in Own Shares
2nd Oct 20194:30 pmRNSHolding(s) in Company
2nd Oct 20193:30 pmRNSAdditional Listing
1st Oct 201912:30 pmRNSTotal Voting Rights
27th Sep 201912:30 pmRNSTransaction in Own Shares
20th Sep 201912:00 pmRNSTransaction in Own Shares
13th Sep 201911:30 amRNSTransaction in Own Shares
13th Sep 201911:00 amRNSDirector/PDMR Shareholding
13th Sep 201910:30 amRNSBlock Listing
10th Sep 20193:00 pmRNSDirector/PDMR Shareholding
6th Sep 201911:30 amRNSTransaction in Own Shares
4th Sep 201911:30 amRNSHolding(s) in Company
2nd Sep 20191:30 pmRNSTotal Voting Rights
30th Aug 201911:30 amRNSTransaction in Own Shares
28th Aug 20191:00 pmRNSChanges to senior management

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.